Result and financial position Q2 April - June 2023

Income for the quarter amounted to 1 776  kSEK (0 kSEK).
 
Operating expenses amounted to 6 836  kSEK (7 876 kSEK), of which personnel costs amounted to 3 160 kSEK (2 838 kSEK).
 
Other external costs amounted to  3 372 kSEK (4 709 kSEK).
 
Operating result amounted to  -5 060 kSEK (-7 873 kSEK) and result after financial items amounted to -4 965 kSEK (-7 882 kSEK).
 
Result amounted to -4 965 kSEK (-7 882 kSEK ).
 
Result per share before and after dilution amounted to  0.36 SEK (-0.57 SEK).
 
Cash flow during the quarter amounted to -4 440 kSEK (-7 587 kSEK). Cash flow per share amounted to -0.32 SEK (-0.55SEK). 

Revenues for the quarter amounted to 1.8 mSEK of which  1.1 mSEK derives from a feasibility study with LaminarPace for ambient drying of mRNA/LNP materials and/or mRNA vaccine(s) and  638 kSEK from the ongoing Eurostars-project. The result follows expectations regarding the income from the Eurostars grant and the costs of the ongoing commercialization of LaminarPace technology. The decrease of external costs is mainly driven by lower consulting fees. 

Result and financial position H1 - reporting period (Jan-June) 2023

Income for the period amounted to 2 414 kSEK (0 kSEK).
 
Operating expenses amounted to 12 409 kSEK (14 225 kSEK), of which personnel costs amounted to  5 938 kSEK (6 115 kSEK).
 
Other external costs amounted to 5 865 kSEK  (7 460 kSEK).

Operating result amounted to -9 995 kSEK (-14 213 kSEK) and result after financial items amounted to -9 837 kSEK (-14 167 kSEK). 
 
Result for the period amounted to -9 837 kSEK (-14 167 kSEK).
 
Earnings per share before and after dilution amounted to -0.71 SEK (-1.03).
 
Cash flow during the period amounted to -8 368 kSEK (24 374 kSEK). The cashflow H1 2022 included a share issue of 28 051 kSEK. Cash flow per share amounted to SEK -0.61 (1.85). 

Cash and cash equivalents as of June 30 2023 amounted to  14 583 kSEK, compared with 36 647 kSEK on June 30 2022. 

The company's equity as of June 30 2023 amounted to 19 683 kSEK, compared with 43 705 kSEK on June 30 2022.

Equity per share as of June 30 2023 amounted to  1.43 SEK, compared with 3.17 SEK on June 30 2022. 

The company's equity ratio as of June 30 2023 was 80% compared to 86% on June 30 2022. 

Revenues for the period amounted to 2.4 mSEK.  1.1 mSEK is from feasibility study regarding LaminarPace for ambient drying of mRNA/LNP materials and/or mRNA vaccine(s) and 1.3 mSEK from the ongoing Eurostars-project. The result follows expectations regarding the income from the Eurostars grant and the costs of the ongoing commercialization of LaminarPace technology. The decrease of external costs is mainly driven by lower consulting fees.